Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bradford
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Bradford, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 12 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sanofi8 AstraZeneca6 Boehringer Ingelheim4 GlaxoSmithKline4 Hoffmann-La Roche2
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Bradford

56 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
NCT07575308Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
DrugALN-6400
Alnylam Pharmaceuticals
Phase 2
24
Bradford, Oxford, Truro
2026-07-30
Recruiting
Boehringer Ingelheim
Phase 2
132
Bradford, London, Salford
2026-03-23
Recruiting
GlaxoSmithKline
Phase 3
456
Bradford
2026-03-13
Active, closed
Sanofi
Phase 3
59
Wigan, Bradford
2026-03-12
Recruiting
Boehringer Ingelheim
Phase 3
286
Bebington, Bradford, Cambridge, Carshalton, Leicester, London, Middlesbrough, Salford
2026-02-16
Active, closed
Kailera
Phase 3
2,530
Soham, Torpoint, Hull, Stevenage, Leicester, Nottingham, Newcastle upon Tyne, Bradford
2025-12-18
Recruiting
Prima Mente
Observational
1,000
London, Newport, Bradford, Bridgend, Llanelli, Newcastle upon Tyne, Penarth, Reading
2025-11-13
Recruiting
GlaxoSmithKline
Phase 3
1,196
Bedford, Bradford, Corby
2025-10-20
Recruiting
Gesynta Pharma AB
Phase 2
190
Bradford, Bristol, Corby, Coventry, London, Northwood, Norwich, Orpington
2025-10-15
Recruiting
Merck Sharp & Dohme LLC
Phase 2
315
Norwich, Bath, Barnet, Bradford
2025-09-26
Recruiting
Sanofi
Phase 4
218
Dundee, Newcastle upon Tyne, Southampton, Leicester, Bradford, Sheffield
2025-09-22
Recruiting
PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB
NCT06789406Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Overactive Bladder (OAB)
Axonics, Inc.
Not applicable
55
Bradford, Wakefield, Leeds, London
2025-09-18
Active, closed
Hoffmann-La Roche
Phase 3
1,101
Bradford, Bristol, Chertsey, London, Newcastle, York
2025-09-17
Recruiting
Sanofi
Phase 3
942
Bristol, London, Leicester, Harrow, Oxford, Worthing, Bradford
2025-09-16
Recruiting
4D Molecular Therapeutics
Phase 3
480
Bradford, London, Sunderland
2025-07-22
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Birmingham, Blackburn, Bournemouth, Bradford, Bristol, Bromborough, Chichester, Cosham
2025-07-22
Recruiting
AstraZeneca
Phase 2
987
Bradford, Cottingham, Glasgow, Harrow, London, Newcastle upon Tyne, Thetford, Wythenshawe
2025-06-27
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Belfast, Birmingham, Blackpool, Bradford, Bristol, Cambridge, Cardiff, Dundee, Scotland
2025-06-09
Active, closed
Upstream Bio Inc.
Phase 2
396
Cottingham, Glasgow, Chertsey, Perth, Bradford, Oxford
2025-05-21
Recruiting
Pfizer
Phase 2
252
Bradford, Cambridge, Manchester, London, Crumpsall, Wakefield
2025-05-20
Recruiting
AstraZeneca
Phase 3
400
Belfast, Birmingham, Bradford, Bristol, Chorley, Leeds, Liverpool, Nottingham
2025-03-28
Active, closed
Apogee Therapeutics, Inc.
Phase 1
31
Bradford, Manchester
2025-03-27
Recruiting
AstraZeneca
Phase 3
990
Bradford, Brighton, Cottingham, Glasgow, Halifax, Leeds, Portsmouth, Tyne and Wear
2025-03-18
Recruiting
Takeda
Phase 3
600
London, Coventry, Bradford, Harlow, Oxford, Stoke-on-Trent, Wolverhampton
2025-03-10
Recruiting
AstraZeneca
Phase 3
5,000
Bradford, Bristol, Canterbury, Cardiff, Dundee, Glasgow, Hounslow, London
2025-03-03
Active, closed
Sanofi
Phase 3
231
London, Oxford, Bradford, Newcastle upon Tyne
2025-02-12
Active, closed
GlaxoSmithKline
Phase 2
307
Bradford, London, Newcastle upon Tyne
2025-02-10
Active, closed
Sanofi
Phase 2
556
Ruislip, Corby, Nottingham, Oxford, Barnsley, Bradford, London
2024-11-07
Recruiting
argenx
Phase 3
69
Birmingham, Bradford, Coventry, Glasgow, Leicester, London, Truro
2024-10-18
Active, closed
Ipsen
Observational
424
Aberdeen, Belfast, Birmingham, Bradford, Hull, London, Newcastle, Nottingham
2024-10-14
By invitation
Sanofi
Phase 2
900
Cambridge, Glasgow, Bradford, Chertsey, London
2024-09-30
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
London, Maidstone, Middlesbrough, Oxford, Sheffield, Birmingham, Bradford, Bristol
2024-09-11
Active, closed
Uniquity One (UNI)
Phase 2
182
Wythenshawe, Bradford, High Wycombe, London
2024-08-14
Active, closed
EyeBiotech Ltd.
Phase 2/3
984
London, York, Bradford, Bristol, Liverpool, Sunderland, Wolverhampton
2024-08-07
Recruiting
GlaxoSmithKline
Phase 3
150
Bradford, London, Southampton
2024-07-19
Recruiting
CSL Behring
Phase 2/3
3,110
Birmingham, Bradford, Coventry, Derby, Dorchester, Liverpool, London, Londonderry
2024-04-27
Recruiting
AstraZeneca
Phase 3
5,250
Bicester, Bollington, Bradford, Cardiff, Chesterfield, Corby, Cottingham, Fowey
2024-02-21
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Aberdeen, Birmingham, Boston, Bradford, Liverpool, London, Newport
2024-02-05
By invitation
Sanofi
Phase 3
90
Birmingham, Leicester, London, Bradford
2024-01-03
Active, closed
Avacostar - (PASS)
NCT05897684ANCA-associated Vasculitis
Vifor Fresenius Medical Care Renal Pharma
Observational
507
Birmingham, Bradford, Bristol, Cambridge, Canterbury, Cardiff, Carshalton, Coventry
2023-09-11
Recruiting
AstraZeneca
Phase 3
231
Birmingham, Bradford, Bristol, Glasgow, Leicester, London, Nottingham, Stoke-on-Trent
2023-08-24
Active, closed
Hoffmann-La Roche
Phase 3
2,000
Cambridge, London, Bellshill, Bradford, Cardiff, Chesterfield, Chorley, Cottingham
2023-06-28
Active, closed
Novo Nordisk A/S
Phase 3
7,101
Blackpool, Birmingham, Chichester, Bradford, Bradford on Avon, Bristol, Chester, Coventry
2023-03-01
Active, closed
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
NCT05797896Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration
Complement Therapeutics
Observational
250
Belfast, Bradford, Frimley, Gloucester, Liverpool, London, Manchester, Newcastle
2023-02-07
Recruiting
Iperboreal Pharma Srl
Phase 3
170
Birmingham, Bradford, Brighton, Canterbury, London, Oxford, Sheffield, Stoke-on-Trent
2022-12-14
Active, closed
Amgen
Phase 3
7,297
Belfast, Birmingham, Blackpool, Bradford, Bristol, Chichester, Chippenham, Craigavon
2022-12-14
Active, closed
Bellus Health Inc. - a GSK company
Phase 3
997
Belfast, Bradford, Bristol, Chelmsford, Corby, Coventry, Hayle, Hull
2022-12-05
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Bradford, London
2022-07-14
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Aylesbury, London, Gloucester, Southampton, Oxford, Leeds, Bradford, Bristol
2022-01-13
Active, closed
Sanofi
Phase 4
1,339
Cambridge, Oxford, Bradford, Liverpool, Newcastle upon Tyne, Wakefield
2021-12-16
Active, closed
Beeline Medicines Corporation
Phase 2
248
Cambridge, Bradford, Manchester
2021-10-11
Active, closed
Janssen Research & Development, LLC
Phase 4
411
Barnet, Bradford, Coventry, Leeds, Manchester, Newcastle, Stoke-on-Trent
2021-08-30
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Bradford, Cambridge, London, Londonderry, North Shields, Portadown, Sheffield, Stevenage
2021-08-14
Active, closed
Bristol-Myers Squibb
Phase 3
729
London, Bradford, Hull, Liverpool, Manchester
2021-07-15
Active, closed
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
NCT04056247Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer
OncoHost Ltd.
Observational
10,000
Aberdeen, Bournemouth, Bradford, Cheltenham, Haverfordwest, Northwood, Shrewsbury, South Shields
2019-10-01
Active, closed
REDUCER-I: An Observational Study of the Neovasc Reducer™ System
NCT02710435Angina Pectoris, Angina Pectoris, Stable, Chronic Stable Angina
Shockwave Medical, Inc.
Observational
400
Bradford, Edinburgh, London
2016-03
Rows per page Showing 1–56 of 56
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-uk/city/bradford

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 12 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 56 of those studies with a site in Bradford.

How many clinical trials are recruiting in Bradford?

27 of the 56 studies on this page are recruiting new participants as of the 12 Oct 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 26 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bradford), 56 studies
PhaseStudiesRecruitingShare
Phase 3311755.4%
Phase 212621.4%
Observational6110.7%
Phase 4315.4%
Phase 2/3213.6%
Not applicable111.8%
Phase 1101.8%

Most active sponsors

Lead sponsors with the most studies (Bradford)
Lead sponsorStudiesRecruiting
Sanofi82
AstraZeneca66
Boehringer Ingelheim44
GlaxoSmithKline43
Hoffmann-La Roche20
4D Molecular Therapeutics11
AbbVie10
Alnylam Pharmaceuticals11
Amgen10
Apogee Therapeutics, Inc.10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.